What is Wedbush’s Forecast for XENE FY2029 Earnings?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Research analysts at Wedbush issued their FY2029 earnings estimates for Xenon Pharmaceuticals in a report issued on Thursday, January 23rd. Wedbush analyst L. Chico expects that the biopharmaceutical company will post earnings of $5.54 per share for the year. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.13) per share.

Other equities analysts also recently issued research reports about the company. Raymond James reaffirmed an “outperform” rating and issued a $50.00 price objective on shares of Xenon Pharmaceuticals in a research report on Thursday, October 10th. Needham & Company LLC restated a “buy” rating and issued a $60.00 price target on shares of Xenon Pharmaceuticals in a report on Wednesday, November 13th. Finally, HC Wainwright restated a “buy” rating and issued a $53.00 target price on shares of Xenon Pharmaceuticals in a research note on Thursday, December 12th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Xenon Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $56.00.

Xenon Pharmaceuticals Stock Up 2.0 %

XENE opened at $39.98 on Friday. The stock’s 50 day moving average price is $40.23 and its 200-day moving average price is $40.79. Xenon Pharmaceuticals has a one year low of $35.53 and a one year high of $50.99.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.01. During the same quarter in the prior year, the company earned ($0.73) EPS.

Insider Transactions at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, CFO Sherry Aulin sold 18,709 shares of the business’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $41.21, for a total transaction of $770,997.89. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Gary Patou sold 4,891 shares of the firm’s stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $41.08, for a total value of $200,922.28. Following the completion of the transaction, the director now owns 23,573 shares of the company’s stock, valued at approximately $968,378.84. The trade was a 17.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.52% of the company’s stock.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC lifted its stake in Xenon Pharmaceuticals by 2.2% during the 3rd quarter. FMR LLC now owns 6,917,684 shares of the biopharmaceutical company’s stock valued at $272,349,000 after acquiring an additional 149,511 shares during the period. Driehaus Capital Management LLC boosted its stake in shares of Xenon Pharmaceuticals by 2.3% during the 2nd quarter. Driehaus Capital Management LLC now owns 4,419,472 shares of the biopharmaceutical company’s stock worth $172,315,000 after acquiring an additional 97,732 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Xenon Pharmaceuticals by 0.4% during the 3rd quarter. Wellington Management Group LLP now owns 3,843,447 shares of the biopharmaceutical company’s stock valued at $151,317,000 after acquiring an additional 15,226 shares during the period. Braidwell LP increased its stake in shares of Xenon Pharmaceuticals by 5.7% in the 3rd quarter. Braidwell LP now owns 2,707,255 shares of the biopharmaceutical company’s stock valued at $106,585,000 after purchasing an additional 146,682 shares in the last quarter. Finally, Janus Henderson Group PLC raised its holdings in Xenon Pharmaceuticals by 144.2% in the 3rd quarter. Janus Henderson Group PLC now owns 2,552,392 shares of the biopharmaceutical company’s stock worth $100,506,000 after purchasing an additional 1,507,135 shares during the period. Institutional investors and hedge funds own 95.45% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.